ASND vs. VEEV: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ASND and VEEV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
VEEV’s market capitalization of 46.46 billion USD is significantly greater than ASND’s 10.52 billion USD, highlighting its more substantial market valuation.
VEEV carries a higher beta at 0.99, indicating it’s more sensitive to market moves, while ASND (beta: 0.36) exhibits greater stability.
ASND trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, VEEV is a standard domestic listing.
| Symbol | ASND | VEEV |
|---|---|---|
| Company Name | Ascendis Pharma A/S | Veeva Systems Inc. |
| Country | DK | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Healthcare Information Services |
| CEO | Jan Moller Mikkelsen | Peter P. Gassner |
| Price | 174.18 USD | 284.29 USD |
| Market Cap | 10.52 billion USD | 46.46 billion USD |
| Beta | 0.36 | 0.99 |
| Exchange | NASDAQ | NYSE |
| IPO Date | January 28, 2015 | October 16, 2013 |
| ADR | Yes | No |
Historical Performance
This chart compares the performance of ASND and VEEV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ASND
191.42%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ASND’s Return on Equity of 191.42% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
VEEV
13.74%
Medical - Healthcare Information Services Industry
- Max
- 25.87%
- Q3
- 8.12%
- Median
- 2.99%
- Q1
- -18.32%
- Min
- -48.18%
In the upper quartile for the Medical - Healthcare Information Services industry, VEEV’s Return on Equity of 13.74% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ASND
-50.64%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ASND has a negative Return on Invested Capital of -50.64%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
VEEV
9.39%
Medical - Healthcare Information Services Industry
- Max
- 26.81%
- Q3
- 8.81%
- Median
- 2.09%
- Q1
- -11.56%
- Min
- -32.60%
In the upper quartile for the Medical - Healthcare Information Services industry, VEEV’s Return on Invested Capital of 9.39% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ASND
-92.67%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ASND has a negative Net Profit Margin of -92.67%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
VEEV
27.34%
Medical - Healthcare Information Services Industry
- Max
- 39.13%
- Q3
- 9.34%
- Median
- 1.37%
- Q1
- -15.05%
- Min
- -39.66%
A Net Profit Margin of 27.34% places VEEV in the upper quartile for the Medical - Healthcare Information Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ASND
-90.54%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ASND has a negative Operating Profit Margin of -90.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
VEEV
26.97%
Medical - Healthcare Information Services Industry
- Max
- 39.94%
- Q3
- 11.27%
- Median
- 3.94%
- Q1
- -9.81%
- Min
- -29.30%
An Operating Profit Margin of 26.97% places VEEV in the upper quartile for the Medical - Healthcare Information Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ASND | VEEV |
|---|---|---|
| Return on Equity (TTM) | 191.42% | 13.74% |
| Return on Assets (TTM) | -32.19% | 10.05% |
| Return on Invested Capital (TTM) | -50.64% | 9.39% |
| Net Profit Margin (TTM) | -92.67% | 27.34% |
| Operating Profit Margin (TTM) | -90.54% | 26.97% |
| Gross Profit Margin (TTM) | 85.30% | 75.50% |
Financial Strength
Current Ratio
ASND
1.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ASND’s Current Ratio of 1.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
VEEV
4.60
Medical - Healthcare Information Services Industry
- Max
- 5.37
- Q3
- 3.30
- Median
- 1.91
- Q1
- 1.37
- Min
- 0.54
VEEV’s Current Ratio of 4.60 is in the upper quartile for the Medical - Healthcare Information Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio
ASND
-4.46
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
ASND has a Debt-to-Equity Ratio of -4.46, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.
VEEV
0.01
Medical - Healthcare Information Services Industry
- Max
- 1.14
- Q3
- 0.65
- Median
- 0.16
- Q1
- 0.04
- Min
- 0.00
Falling into the lower quartile for the Medical - Healthcare Information Services industry, VEEV’s Debt-to-Equity Ratio of 0.01 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio
ASND
-3.72
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ASND has a negative Interest Coverage Ratio of -3.72. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
VEEV
--
Medical - Healthcare Information Services Industry
- Max
- 12.12
- Q3
- 3.11
- Median
- 1.20
- Q1
- -12.03
- Min
- -25.76
Interest Coverage Ratio data for VEEV is currently unavailable.
Financial Strength at a Glance
| Symbol | ASND | VEEV |
|---|---|---|
| Current Ratio (TTM) | 1.04 | 4.60 |
| Quick Ratio (TTM) | 0.71 | 4.60 |
| Debt-to-Equity Ratio (TTM) | -4.46 | 0.01 |
| Debt-to-Asset Ratio (TTM) | 0.80 | 0.01 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.34 | -2.39 |
| Interest Coverage Ratio (TTM) | -3.72 | -- |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ASND and VEEV. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ASND
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ASND currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
VEEV
0.00%
Medical - Healthcare Information Services Industry
- Max
- 7.19%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VEEV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ASND
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ASND has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
VEEV
0.00%
Medical - Healthcare Information Services Industry
- Max
- 130.89%
- Q3
- 2.61%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VEEV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ASND | VEEV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ASND
-25.98
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ASND has a negative P/E Ratio of -25.98. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
VEEV
59.27
Medical - Healthcare Information Services Industry
- Max
- 114.57
- Q3
- 67.12
- Median
- 45.42
- Q1
- 28.19
- Min
- 6.48
VEEV’s P/E Ratio of 59.27 is within the middle range for the Medical - Healthcare Information Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ASND
-2.36
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ASND has a negative Forward PEG Ratio of -2.36. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
VEEV
4.64
Medical - Healthcare Information Services Industry
- Max
- 6.35
- Q3
- 2.93
- Median
- 2.00
- Q1
- 0.55
- Min
- 0.03
A Forward PEG Ratio of 4.64 places VEEV in the upper quartile for the Medical - Healthcare Information Services industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
Price-to-Sales Ratio
ASND
24.22
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ASND’s P/S Ratio of 24.22 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
VEEV
16.27
Medical - Healthcare Information Services Industry
- Max
- 10.90
- Q3
- 5.95
- Median
- 2.46
- Q1
- 1.42
- Min
- 0.36
With a P/S Ratio of 16.27, VEEV trades at a valuation that eclipses even the highest in the Medical - Healthcare Information Services industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio
ASND
-46.77
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
VEEV
7.45
Medical - Healthcare Information Services Industry
- Max
- 12.91
- Q3
- 6.69
- Median
- 2.84
- Q1
- 1.88
- Min
- 1.03
The P/B Ratio is often not a primary valuation metric for the Medical - Healthcare Information Services industry.
Valuation at a Glance
| Symbol | ASND | VEEV |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -25.98 | 59.27 |
| Forward PEG Ratio (TTM) | -2.36 | 4.64 |
| Price-to-Sales Ratio (P/S, TTM) | 24.22 | 16.27 |
| Price-to-Book Ratio (P/B, TTM) | -46.77 | 7.45 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -29.03 | 38.59 |
| EV-to-EBITDA (TTM) | -37.74 | 56.35 |
| EV-to-Sales (TTM) | 25.11 | 15.61 |